TJ Chao reviews key safety considerations when prescribing ruxolitinib cream 1.5% for atopic dermatitis, with a focused discussion on understanding and communicating black box warnings. The session emphasizes the importance of clear, accurate patient counseling to ensure informed decision-making and appropriate risk–benefit assessment.
Topics Covered:
- Overview of black box warnings associated with topical JAK inhibitors
- Safety data specific to ruxolitinib cream 1.5%
- Strategies for discussing adverse events with patients and caregivers
- Practical counseling tips to support adherence and shared decision-making
Explore Related Resources:
